Critical Care ECMO with Dr. Jon Marinaro, Dr. Gary Schwartz and Dr. Cedrick Spak – Episode 103
Key Points: ECMO in HIV/AIDS Patients
1. HIV Is No Longer a Strong Contraindication to ECMO
-
Historically, HIV and severe immunosuppression were considered relative contraindications for ECMO.
-
With modern antiretroviral therapy (ART), outcomes have dramatically improved.
-
Patients with HIV who receive effective ART can recover immune function and achieve near-normal life expectancy.
-
Therefore, HIV alone should not exclude patients from ECMO candidacy.
2. Immune Reconstitution Makes Recovery Possible
-
ART can rapidly suppress viral load and restore immune function.
-
Patients with very low CD4 counts (even <10) can recover to normal CD4 counts (>800) over time.
-
This means even severely immunocompromised patients may recover if given time and support.
-
ECMO can act as a bridge to immune recovery.
3. ECMO Functions as a “Pause Button”
-
ECMO stabilizes respiratory or cardiac failure while clinicians:
-
Treat infections
-
Start ART
-
Manage complications
-
-
This buys time for reversible disease processes to recover.
4. Major Cause of Respiratory Failure: Pneumocystis Pneumonia
Common features in HIV patients requiring ECMO:
-
Pneumocystis jirovecii pneumonia (PJP)
-
Severe respiratory failure
-
Cystic lung destruction
-
Frequent bronchopleural fistulas and pneumothorax
Ventilation can worsen these conditions.
Thus ECMO is used to:
-
Reduce ventilator pressure
-
Prevent further lung damage
-
Allow lung healing.
5. Ventilator Strategy: Minimize Positive Pressure
Typical strategy:
-
Rapid ECMO initiation if ventilation causes lung injury
-
Attempt early extubation
-
If needed:
-
tracheostomy
-
minimal ventilator settings
-
Example “rest settings” described:
-
Driving pressure ≈ 10
-
PEEP ≈ 10 (often reduced further)
-
FiO₂ ≈ 50%
Goal: avoid further lung trauma.
6. ECMO Candidate Selection
Primary question:
Is the disease reversible?
If yes → ECMO should be considered.
Factors supporting ECMO:
-
Young patient
-
Treatable infection
-
Potential immune recovery
Possible relative contraindications:
-
Severe fungal infection
-
Multiple uncontrolled opportunistic infections
-
Extreme cachexia or severe systemic deterioration.
7. Early ART Should Be Started
Modern approach:
-
Start antiretroviral therapy during acute illness
-
Do not delay until after ICU discharge
Benefits:
-
Rapid viral suppression
-
Faster immune recovery
Risk:
-
Immune Reconstitution Inflammatory Syndrome (IRIS)
-
Temporary worsening of infection due to immune rebound.
-
8. Circuit and Infection Complications
Important ECMO considerations in HIV patients:
-
Increased risk of circuit thrombosis
-
Possible fungemia
-
If fungemia occurs:
-
circuit replacement
-
possible re-cannulation
-
These complications require careful monitoring.
9. Cannulation Strategy
Example high-volume center approach:
-
Bilateral femoral VV ECMO cannulation
-
Fast
-
Reliable flow
-
Allows later neck access if needed
-
Used especially during high-volume periods (e.g., COVID).
10. Outcomes and Indication Expansion
ECMO indications are evolving:
-
Older age
-
Longer ventilator times
-
HIV/AIDS
-
Cancer patients
All are examples of “indication creep” as experience grows.
The key principle remains:
ECMO should be used if there is a realistic chance of recovery.
11. Resource and Program Considerations
Decision-making must consider:
-
Resource availability
-
Program experience
-
Institutional risk tolerance
High-volume ECMO centers can often accept higher-risk patients.
12. Broader Lesson
Medical contraindications often change with new technology and therapies.
Example given:
-
HIV was once a contraindication for kidney transplantation
-
Now it is accepted due to improved treatment.
The same evolution may be happening with ECMO indications.


